Phase III Study: Safety & Efficacy of Daptomycin Compared to Conventional Therapy in the Treatment of Subjects w/ infective endocarditis or bacteremia due to Staphylococcus aureus |
United States |
Opportunistic Infection |
|
|
Proposed Experiments to Study Emergence of Antimicrobial Resistance in Methicillin- Resistant Strains of Staphylococcus aureus |
United States |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Penicillin Interactive Proteins of Staphylococcus Aureus |
United States |
|
|
|
Biology of Infectious Diseases Training Program [I] |
United States |
Training and Capacity Building |
|
|
Applied Research on Antimicrobioal Resistance: Molecular Epidemiology of Community Methicillin-resistant Staphylococcus aureus (MRSA) |
United States |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Protocol Development for a Phase 2 Study Evaluating the Safety and Feasibility of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia |
United States |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Phase 2 Study, Safety of and Rate of Bacterial Clearance of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia |
United States |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
A Phase 2, Randomized, Open-Labeled Study on the Safety of and Rate of Bacterial Clearance of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia |
United States |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Multidrug-Resistant CA-MRSA Infections Among HIV+ Persons: CA AIDS Grant ID07-REI-129 |
United States |
Infectious Disease, Sexually Transmitted Infections (STIs), Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Epidemiology and Surveillance |
|
|
Tetrezolid vs. Daptomycin and Vancomycin for Treatment of Experimental Staphylococcus aureus |
United States |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Ceftobiprole vs. Daptomycin and Linezolid for Treatment of Experimental Staph. aureus Endocarditis in Rabbits |
United States |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Rifabutin Based Therapy for Eradication of Staph Carriage in HIV-Infected Individuals with Prior Skin Structure Infections |
United States |
HIV/AIDS, Opportunistic Infection |
|
|
Prevention Umbrella for MSM in the Americas |
Brazil; Peru |
HIV/AIDS, Risk Reduction and Prevention |
|
|
Epidemiologic Analysis of Data from Project Aware to Determine the Impact of Different HIV Testing Strategies on Risk Behaviors and STD Rates among HIV-Uninfected MSM |
United States |
HIV/AIDS |
|
|
Efficacy Evaluation and Safety of Single-dose IV Oritavancin vs. IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infection (SOLO I) |
United States |
Infectious Disease |
|
|
Biology of Infectious Diseases Training Program [II] |
United States |
Training and Capacity Building |
|
|
Novel Mechanisms of Beta-Lactam Resistance in Staph aureus |
United States |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Prevention Umbrella for MSM in the Americas |
Brazil; Peru |
HIV/AIDS |
|
|
A Clinical Trial for Uncomplicated Skin Infections in Areas of Epidemic Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) |
United States |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Opportunistic Infection |
|
|
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Patients with Blood Stream Infections due to Staphylococci. |
United States |
|
|
|
Antibacterial Resistance Leadership Group (ARIG) |
United States |
Zoonosis, Emerging Disease, and Drug Resistance, Systematic Reviews and Guideline Development |
|
|
Novel Mechanisms of Beta-Lactam Resistance in Staph Aureus |
United States |
Noncommunicable and/or Chronic Disease, Risk Reduction and Prevention |
|
|
Study for Sample Acquisition for Patients Diagnosed with S. aureus Bacteremia |
United States |
Infectious Disease, Drug and Diagnostics Development, Epidemiology and Surveillance |
|
|
Biology of Infectious Diseases Training Program |
United States |
Infectious Disease, Residencies, Fellowships, and Postdoctoral Training |
|
|
Biology of Infectious Diseases Training Program [III] |
United States |
Training and Capacity Building |
|
|
Novel Mechanisms of Beta-lactam Resistance in Staph Aureus |
United States |
Genetics |
|
|
Novel Mechanisms of Beta-lactam Resistance in Staph Aureus, Continuation A120553 |
United States |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Ceftaroline Fosamil in Subjects With Staphylococcus aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia |
United States |
|
|
|
Biology of Infectious Diseases Training Program |
United States |
Infectious Disease, Training and Capacity Building |
|
|